» Articles » PMID: 37628864

Conditional Loss of MEF2C Expression in Osteoclasts Leads to a Sex-Specific Osteopenic Phenotype

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Aug 26
PMID 37628864
Authors
Affiliations
Soon will be listed here.
Abstract

Myocyte enhancement factor 2C (MEF2C) is a transcription factor studied in the development of skeletal and smooth muscles. Bone resorption studies have exhibited that the reduced expression of MEF2C contributes to osteopetrosis and the dysregulation of pathological bone remodeling. Our current study aims to determine how MEF2C contributes to osteoclast differentiation and to analyze the skeletal phenotype of cKO mice (; ). qRT-PCR and Western blot demonstrated that expression is highest during the early days of osteoclast differentiation. Osteoclast genes, including c, , , and , had a significant reduction in expression, along with a reduction in osteoclast size. Despite reduced CTX activity, female cKO mice were osteopenic, with decreased bone formation as determined via a P1NP ELISA, and a reduced number of osteoblasts. There was no difference between male WT and cKO mice. Our results suggest that is critical for osteoclastogenesis, and that its dysregulation leads to a sex-specific osteopenic phenotype.

Citing Articles

Lysine specific demethylase 1 conditional myeloid cell knockout mice have decreased osteoclast differentiation due to increased IFN- gene expression.

Astleford-Hopper K, Abrahante Llorens J, Bradley E, Mansky K JBMR Plus. 2024; 9(1):ziae142.

PMID: 39664933 PMC: 11632826. DOI: 10.1093/jbmrpl/ziae142.


Bone Disease in Primary Hyperparathyroidism-Changes Occurring in Bone Metabolism and New Potential Treatment Strategies.

Iwanowska M, Kochman M, Szatko A, Zgliczynski W, Glinicki P Int J Mol Sci. 2024; 25(21).

PMID: 39519190 PMC: 11546563. DOI: 10.3390/ijms252111639.


STW-MD: a novel spatio-temporal weighting and multi-step decision tree method for considering spatial heterogeneity in brain gene expression data.

Mao S, Huang X, Chen R, Zhang C, Diao Y, Li Z Brief Bioinform. 2024; 25(2).

PMID: 38385881 PMC: 10883420. DOI: 10.1093/bib/bbae051.

References
1.
Blixt N, Norton A, Zhang A, Aparicio C, Prasad H, Gopalakrishnan R . Loss of myocyte enhancer factor 2 expression in osteoclasts leads to opposing skeletal phenotypes. Bone. 2020; 138:115466. PMC: 7443313. DOI: 10.1016/j.bone.2020.115466. View

2.
Kim J, Lin C, Stavre Z, Greenblatt M, Shim J . Osteoblast-Osteoclast Communication and Bone Homeostasis. Cells. 2020; 9(9). PMC: 7564526. DOI: 10.3390/cells9092073. View

3.
Pon J, Marra M . MEF2 transcription factors: developmental regulators and emerging cancer genes. Oncotarget. 2015; 7(3):2297-312. PMC: 4823036. DOI: 10.18632/oncotarget.6223. View

4.
Sims N, Martin T . Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit. Bonekey Rep. 2014; 3:481. PMC: 3899560. DOI: 10.1038/bonekey.2013.215. View

5.
Potthoff M, Olson E . MEF2: a central regulator of diverse developmental programs. Development. 2007; 134(23):4131-40. DOI: 10.1242/dev.008367. View